Zai Lab Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZLAB Nasdaq 2836 www.zailaboratory.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zai Lab Limited

Zai Lab (ZLAB) Draws Fresh Optimism, Is The Stock Still 24% Undervalued? - Nov 7th, 2026 1:15 am
Zai Lab Ltd (ZLAB) Q3 2026 Earnings Call Highlights: Stabilizing China Business, Breakthrough ... - Nov 6th, 2026 10:07 pm
Zai Lab Q3 Earnings Call Highlights - Nov 6th, 2026 5:14 pm
Zai Lab Q3 Performance Meets Expectations With Pivotal 2027 Ahead, UBS Says - Nov 6th, 2026 10:42 am
Zai Lab (ZLAB) Q3 2026 Earnings Call Transcript - Nov 5th, 2026 2:18 pm
Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas - Nov 5th, 2026 7:00 am
Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Nov 5th, 2026 6:30 am
Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates - Nov 5th, 2026 4:30 am
Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - Oct 27th, 2026 8:40 am
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - Oct 23rd, 2026 8:40 am
Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study - Oct 23rd, 2026 8:03 am
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer - Oct 23rd, 2026 6:04 am
Zai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer Trial - Oct 23rd, 2026 5:41 am
Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer - Oct 23rd, 2026 4:33 am
Zai Lab Announces $250 Million Private Placement - Oct 22nd, 2026 6:52 pm
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading - Oct 22nd, 2026 8:39 am
Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026 - Oct 21st, 2026 5:30 am
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading - Oct 19th, 2026 8:52 am
Asian Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - Oct 15th, 2026 8:40 am